Marlies van Dijk1, Jorine E Hartman2, Karin Klooster2, Nick H T Ten Hacken2, Huib A M Kerstjens2, Dirk-Jan Slebos2. 1. University of Groningen, Department of Pulmonary Diseases, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands, m.van.dijk05@umcg.nl. 2. University of Groningen, Department of Pulmonary Diseases, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands.
Abstract
BACKGROUND: For selected patients with severe emphysema, bronchoscopic lung volume reduction with endobronchial valves (EBV) is recognized as an additional treatment option. In most trials investigating EBV treatment, patients with a very low diffusing capacity (DLCO) were excluded from participation. OBJECTIVES: Our goal was to investigate whether EBV treatment in patients with emphysema with a very low DLCO is safe and effective. METHODS: This was a single-center retrospective analysis including patients with emphysema and a DLCO ≤20%pred who underwent EBV treatment. Follow-up was performed 6 months post-treatment. Outcome parameters were compared to a historical matched control group (DLCO >20%pred, matched for sex, age, forced expiratory volume in 1 s [FEV1], and residual volume [RV]). RESULTS: Twenty patients (80% female, 64 ± 6 years, FEV1 26 ± 6%pred, RV 233 ± 45%pred, DLCO 18 ± 1.6%pred) underwent EBV treatment. At 6 months follow-up, we found a statistically significant improvement in FEV1 (0.08 ± 0.12 L), RV (-0.45 ± 0.95 L), 6-min walking distance (38 ± 65 m), and St. George's Respiratory Questionnaire (-12 ± 13 points). With the exception of FEV1, all exceeded the minimal clinically important difference. The most common serious adverse event was a pneumothorax requiring intervention (15%). There were no significant differences in outcome compared to the DLCO >20%pred control group. CONCLUSIONS: In this single-center retrospective analysis, we showed statistically significant and clinically relevant improvements in lung function, exercise capacity, and quality of life up to 6 months after EBV treatment in emphysema patients with a DLCO ≤20% (14-20%) of predicted with no increased risk of serious adverse events.
BACKGROUND: For selected patients with severe emphysema, bronchoscopic lung volume reduction with endobronchial valves (EBV) is recognized as an additional treatment option. In most trials investigating EBV treatment, patients with a very low diffusing capacity (DLCO) were excluded from participation. OBJECTIVES: Our goal was to investigate whether EBV treatment in patients with emphysema with a very low DLCO is safe and effective. METHODS: This was a single-center retrospective analysis including patients with emphysema and a DLCO ≤20%pred who underwent EBV treatment. Follow-up was performed 6 months post-treatment. Outcome parameters were compared to a historical matched control group (DLCO >20%pred, matched for sex, age, forced expiratory volume in 1 s [FEV1], and residual volume [RV]). RESULTS: Twenty patients (80% female, 64 ± 6 years, FEV1 26 ± 6%pred, RV 233 ± 45%pred, DLCO 18 ± 1.6%pred) underwent EBV treatment. At 6 months follow-up, we found a statistically significant improvement in FEV1 (0.08 ± 0.12 L), RV (-0.45 ± 0.95 L), 6-min walking distance (38 ± 65 m), and St. George's Respiratory Questionnaire (-12 ± 13 points). With the exception of FEV1, all exceeded the minimal clinically important difference. The most common serious adverse event was a pneumothorax requiring intervention (15%). There were no significant differences in outcome compared to the DLCO >20%pred control group. CONCLUSIONS: In this single-center retrospective analysis, we showed statistically significant and clinically relevant improvements in lung function, exercise capacity, and quality of life up to 6 months after EBV treatment in emphysemapatients with a DLCO ≤20% (14-20%) of predicted with no increased risk of serious adverse events.
Authors: J Wanger; J L Clausen; A Coates; O F Pedersen; V Brusasco; F Burgos; R Casaburi; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D Johnson; N Macintyre; R McKay; M R Miller; D Navajas; R Pellegrino; G Viegi Journal: Eur Respir J Date: 2005-09 Impact factor: 16.671
Authors: Wouter H van Geffen; Dirk-Jan Slebos; Felix J Herth; Samuel V Kemp; Walter Weder; Pallav L Shah Journal: Lancet Respir Med Date: 2019-02-08 Impact factor: 30.700
Authors: Bruce R Thompson; G Kim Prisk; Philip Peyton; Robert J Pierce; Peter D Rochford Journal: Respir Physiol Neurobiol Date: 2005-04-15 Impact factor: 1.931
Authors: Felix J F Herth; Dirk-Jan Slebos; Gerard J Criner; Arschang Valipour; Frank Sciurba; Pallav L Shah Journal: Respiration Date: 2019-03-05 Impact factor: 3.580
Authors: Franziska C Trudzinski; Anna J Höink; Daniela Leppert; Sebastian Fähndrich; Heinrike Wilkens; Thomas P Graeter; Frank Langer; Robert Bals; Peter Minko; Philipp M Lepper Journal: Respiration Date: 2016-09-08 Impact factor: 3.580
Authors: Alfred Fishman; Fernando Martinez; Keith Naunheim; Steven Piantadosi; Robert Wise; Andrew Ries; Gail Weinmann; Douglas E Wood Journal: N Engl J Med Date: 2003-05-20 Impact factor: 91.245
Authors: Pavlina Lenga; Christoph Ruwwe-Glösenkamp; Christian Grah; Joachim Pfannschmidt; Jens Rückert; Stephan Eggeling; Sven Gläser; Bernd Schmidt; Paul Schneider; Sylke Kurz; Gunda Leschber; Andreas Gebhardt; Birgit Becke; Olaf Schega; Jakob Borchardt; Ralf-Harto Hübner Journal: ERJ Open Res Date: 2021-01-25
Authors: Marlies van Dijk; Rick Sue; Gerard J Criner; Daniela Gompelmann; Felix J F Herth; D Kyle Hogarth; Karin Klooster; Janwillem W H Kocks; Hugo G de Oliveira; Pallav L Shah; Arschang Valipour; Dirk-Jan Slebos Journal: Respiration Date: 2021-06-01 Impact factor: 3.580